Craft

Benitec Biopharma

Stock Price

$10.7

2024-10-28

Market Capitalization

$192 M

2024-10-28

Revenue

$75 K

FY, 2023

Benitec Biopharma Summary

Company Summary

Overview
Benitec Biopharma is a biotechnology company developing a therapeutic platform that combines RNA interference with gene therapy. It aims to provide the silencing of disease-causing genes. The company offers ddRNAi, a technology that allows the development of product candidates in chronic and life-threatening human disease areas, including oculopharyngeal muscular dystrophy and hepatitis B virus.
Type
Public
Status
Active
Founded
2001
HQ
Hayward, CA, US | view all locations
Website
https://benitec.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jerel Banks, Chief Executive Officer & Chairman of the Board

    • Claudia Kloth, Senior Vice President of Manufacturing

      • J. Kevin Buchi, Director

        • Peter Francis, Director

          LocationsView all

          3 locations detected

          • Hayward, CA HQ

            United States

            3940 Trust Way

          • Louisville, KY

            United States

          • Melbourne, VIC

            Australia

            level 14/114 William St

          Benitec Biopharma Financials

          Summary Financials

          Net income (Q3, 2026)
          ($11.9M)
          Cash (Q3, 2026)
          $184.8M
          EBIT (Q3, 2026)
          ($13.6M)
          Enterprise value
          $4.2M

          Footer menu